Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791495 | 0.84 | GAA (0.58) | TSHRCYP3A4RECQLGAAPOLB | |
| SCHEMBL11251960 | 0.83 | SMN1; SMN2 (0.50) | TSHRCYP3A4RECQLGAAPOLB | |
| SCHEMBL3789681 | 0.83 | SMN1; SMN2 (0.44) | TSHRCYP3A4RECQLGAAPOLB | |
| SCHEMBL3398998 | 0.81 | MEN1 (0.50) | TSHRGAAPOLBRAPGEF4LMNA | |
| SCHEMBL7653266 | 0.81 | GAA (0.48) | TSHRCYP3A4RECQLGAAPOLB | |
| Hydrochloric Acid SCHEMBL6518247 | 0.79 | MEN1 (0.48) | TSHRGAAPOLBRAPGEF4LMNA | |
| SCHEMBL12895731 | 0.79 | ALDH1A1 (0.40) | TSHRCYP3A4RECQLGAAPOLB | |
| SCHEMBL21131436 | 0.79 | RAPGEF4 (0.47) | TSHRGAAPOLBRAPGEF4ALDH1A1 | |
| SCHEMBL20673500 | 0.79 | FERMT2 (0.50) | TSHRCYP3A4GAAPOLBRAPGEF4 | |
| SCHEMBL19905565 | 0.79 | ALDH1A1 (0.55) | TSHRGAAPOLBRAPGEF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-7998987-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, ABL1 | TSHR 1448/4885CYP3A4 4029/4885RECQL 4106/4885 |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | TSHR 2959/4885CYP3A4 2021/4885RECQL 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.